1. Home
  2. DAVA vs ZYME Comparison

DAVA vs ZYME Comparison

Compare DAVA & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DAVA
  • ZYME
  • Stock Information
  • Founded
  • DAVA 2000
  • ZYME 2003
  • Country
  • DAVA United Kingdom
  • ZYME United States
  • Employees
  • DAVA N/A
  • ZYME N/A
  • Industry
  • DAVA EDP Services
  • ZYME Biotechnology: Pharmaceutical Preparations
  • Sector
  • DAVA Technology
  • ZYME Health Care
  • Exchange
  • DAVA Nasdaq
  • ZYME Nasdaq
  • Market Cap
  • DAVA 827.6M
  • ZYME 867.6M
  • IPO Year
  • DAVA 2018
  • ZYME 2017
  • Fundamental
  • Price
  • DAVA $15.98
  • ZYME $12.48
  • Analyst Decision
  • DAVA Buy
  • ZYME Buy
  • Analyst Count
  • DAVA 8
  • ZYME 7
  • Target Price
  • DAVA $26.75
  • ZYME $19.50
  • AVG Volume (30 Days)
  • DAVA 813.2K
  • ZYME 499.3K
  • Earning Date
  • DAVA 05-14-2025
  • ZYME 07-31-2025
  • Dividend Yield
  • DAVA N/A
  • ZYME N/A
  • EPS Growth
  • DAVA N/A
  • ZYME N/A
  • EPS
  • DAVA 0.40
  • ZYME N/A
  • Revenue
  • DAVA $1,007,631,882.00
  • ZYME $93,384,000.00
  • Revenue This Year
  • DAVA $6.33
  • ZYME $44.71
  • Revenue Next Year
  • DAVA N/A
  • ZYME $34.57
  • P/E Ratio
  • DAVA $37.71
  • ZYME N/A
  • Revenue Growth
  • DAVA 5.95
  • ZYME 85.05
  • 52 Week Low
  • DAVA $13.39
  • ZYME $8.32
  • 52 Week High
  • DAVA $34.94
  • ZYME $17.70
  • Technical
  • Relative Strength Index (RSI)
  • DAVA 47.20
  • ZYME 50.00
  • Support Level
  • DAVA $13.39
  • ZYME $12.17
  • Resistance Level
  • DAVA $15.44
  • ZYME $12.79
  • Average True Range (ATR)
  • DAVA 0.53
  • ZYME 0.47
  • MACD
  • DAVA 0.10
  • ZYME -0.04
  • Stochastic Oscillator
  • DAVA 50.81
  • ZYME 21.65

About DAVA Endava plc (each representing one)

Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: